Alexander Perl, MD, currently serves as an Associate Professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. He is also a member of the Leukemia Program at the Abramson Cancer Center in Philadelphia, PA.
Dr Perl received his medical degree from the Mount Sinai School of Medicine in New York City, NY, in 1997. After this, he completed a residency in internal medicine at the UCSF Medical Center in San Francisco, CA, followed by a fellowship in medical oncology at the Johns Hopkins Hospital in Baltimore, MA.
Speaking on FLT3 inhibitors for AML and TKIs for ALL
Dr Perl focuses on molecularly targeted therapeutics for acute leukemia, including FLT3 inhibitors for acute myeloid leukemia (AML), tyrosine kinase inhibitors (TKIs) for Ph-like acute lymphoblastic leukemia (ALL) and inhibitors of oncogenic PI3K/AKT/mTOR signaling. Dr Perl is actively involved in clinical research and has coordinated important clinical trials on FLT3 inhibitors for AML.
Dr Perl is also interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia.